2017

150.00 rub.
Buy article
2017/№4

Antihypertensive therapy: From clinical pharmacology to clinical outcome. Or what is important to know when choosing an antihypertensive drug

Zyryanov S. K., Butranova O. I.
Peoples' Friendship University of Russia, Miklukho-Maklaya str. 6, Moscow, Russia 117198

Keywords: hyperpiesis, antihypertensive therapy, antihypertensive drugs

DOI: 10.18087/rhj.2017.4.2381

The article presents the main groups of medicines for the treatment of hypertension, the mechanisms of their hypotensive action, the effectiveness, possible side effects are examined.
  1. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14 Suppl 1: S73–86.
  2. Husain A, Md Sabir Azim, Moloy Mitra, Parminder S. Bhasin. A Review on Candesartan: Pharmacological and Pharmaceutical Profile. Journal of Applied Pharmaceutical Science. 2011;01 (10):12–7.
  3. Verheijen I, Vanderheyden PML, De Backer J-P, Bottari S, Vauquelin G. Antagonist interaction with endogenous AT (1) receptors in human cell lines. Biochem Pharmacol. 2002;64 (8):1207–14.
  4. Vanderheyden PM, Fierens FL, De Backer J, Vauquelin G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors. Biochem Pharmacol. 2000;59 (8):927–35.
  5. Vauquelin G, Morsing P, Fierens FL, De Backer JP, Vanderheyden PM. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem Pharmacol. 2001;61 (3):277–84.
  6. Vauquelin G, Fierens F, Verheijen I, Vanderheyden P. Insurmountable AT (1) receptor antagonism: the need for different antagonist binding states of the receptor. Trends Pharmacol Sci. 2001;22 (7):343–4.
  7. Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular char-acterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor: Olmesartan and telmisartan AT1 receptor binding. British Journal of Pharmacology. 2009;151 (7):952–62. DOI:10.1038/sj.bjp.0707323.
  8. Kiya Y, Miura S -i., Matsuo Y, Karnik SS, Saku K. Abilities of candesartan and other AT1 receptor blockers to impair angiotensin II-induced AT1 receptor activation after wash-out. Journal of the Renin-Angiotensin-Aldosterone System. 2012;13 (1):76–83. DOI:10.1177/1470320311417478.
  9. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004;6 (6):499–506. DOI:10.1038/ncb1137.
  10. Milligan G. Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective. Molecular Pharmacology. 2003;64 (6):1271–6. DOI:10.1124/mol.64.6.1271.
  11. Iekushi K, Taniyama Y, Azuma J, Katsuragi N, Dosaka N, Sanada F et al. Novel Mechanisms of Valsartan on the Treatment of Acute Myocardial Infarction Through Inhibition of the Antiadhesion Molecule Periostin. Hypertension. 2007;49 (6):1409–14. DOI:10.1161/HYPERTENSIONAHA.106.080994.
  12. Vauquelin G, Fierens FL, Gaborik Z, Le Minh T, De Backer J-P, Hunyady L et al. Role of basic amino acids of the human angiotensin type 1 receptor in the binding of the non-peptide antagonist candesartan. Journal of the Renin-Angiotensin-Aldosterone System. 2001;2 (1_suppl): S32–6. DOI:10.1177/14703203010020010501.
  13. Fierens FL, Vanderheyden PM, Gaborik Z, Minh TL, Backer JP, Hunyady L et al. Lys (199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists. J Renin Angiotensin Aldosterone Syst. 2000;1 (3):283–8. DOI:10.3317/jraas.2000.044.
  14. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res. 1995;77 (2):258–65.
  15. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T et al. Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. Journal of Clinical Investigation. 1995;96 (1):438–46. DOI:10.1172/JCI118054.
  16. Unger T. Pharmacology of AT1-receptor blockers. Blood Press Suppl. 2001; (3):5–10.
  17. Van Liefde I, Vauquelin G. Sartan – AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Molecular and Cellular Endocrinology. 2009;302 (2):237–43. DOI:10.1016/j.mce.2008.06.006.
  18. Weisser B, Gerwe M, Michael B, Funken C. Untersuchungen zur antihypertensiven Langzeitwirkung von Candesartan-cilexetil in verschiedenen Dosierungen unter dem Einflu? therapiefreier Intervalle. Arzneimittelforschung. 2011;55 (09):505–13. DOI:10.1055/s-0031–1296897.
  19. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens. 1999;12 (12 Pt 1–2):1181–7.
  20. Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vascular Health and Risk Management. 2011;749. DOI:10.2147/VHRM.S22591.
  21. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The Lancet. 2003;362 (9386):767–71. DOI:10.1016/S0140–6736(03)14283–3.
  22. Vauquelin G, Szczuka A. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation. Neurochemistry International. 2007;51 (5):254–60. DOI:10.1016/j.neuint.2007.05.005.
  23. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362 (9386):777–81. DOI:10.1016/S0140–6736(03)14285–7.
  24. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354 (16):1685–97. DOI:10.1056/NEJMoa060838.
  25. Minatoguchi S, Aoyama T, Kawai N, Iwasa M, Oda M, Kida K et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Pressure. 2013;22 (sup1):29–37. DOI:10.3109/08037051.2013.757844.
  26. Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K et al. Pulse Pressure Lowering Effect of Dual Blockade With Candesartan and Lisinopril vs. High-dose ACE Inhibition in Hypertensive Type 2 Diabetic Subjects: A CALM II Study Post-hoc Analysis. American Journal of Hypertension. 2008;21 (2):172–6. DOI:10.1038/ajh.2007.2.
  27. Hasegawa H, Takano H, Kameda Y, Kubota A, Kobayashi Y, Komuro I. Effect of Switching from Telmisartan, Valsartan, Olmesartan, or Losartan to Candesartan on Morning Hypertension. Clinical and Experimental Hypertension. 2012;34 (2):86–91. DOI:10.3109/10641963.2011.628729.
  28. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003;34 (7):1699–703. DOI:10.1161/01.STR.0000075777.18006.89.
  29. Philipp T, Martinez F, Geiger H, Moulin B, Mourad G, Schmieder R et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrology Dialysis Transplantation. 2010;25 (3):967–76. DOI:10.1093/ndt/gfp581.
  30. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21 (5):875–86. DOI:10.1097/01.hjh.0000059028.82022.89.
  31. Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr Med Res Opin. 2003;19 (5):449–51. DOI:10.1185/030079903125001974.
  32. Chaturvedi N, Porta M, Klein R , Orchard T, Fuller J, Parving HH et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. The Lancet. 2008;372 (9647):1394–402. DOI:10.1016/S0140–6736(08)61412–9.
  33. Sjolie AK, Klein R , Porta M, Orchard T, Fuller J, Parving HH et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. The Lancet. 2008;372 (9647):1385–93. DOI:10.1016/S0140–6736(08)61411–7.
  34. Nakao K, Hirata M, Oba K, Yasuno S, Ueshima K, Fujimoto A et al. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertension Research. 2010;33 (6):600–6. DOI:10.1038/hr.2010.38.
  35. Schupp M, Janke J, Clasen R , Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109 (17):2054–7. DOI:10.1161/01.CIR.0000127955.36250.65.
Zyryanov S. K., Butranova O. I. Antihypertensive therapy: From clinical pharmacology to clinical outcome. Or what is important to know when choosing an antihypertensive drug. Russian Heart Journal. 2017;16(4):286–296

To access this material please log in or register

Register Authorize
Ru En